Predict your next investment

Private Equity
appositecapital.com

See what CB Insights has to offer

Investments

29

Portfolio Exits

7

Funds

4

Service Providers

1

About Apposite Capital

Apposite Capital is an independent investment firm focused exclusively on healthcare. It focuses on companies operating in health and social care, medtech & medical products, pharmaceuticals & life science, and digital health.

Apposite Capital Headquarter Location

Genesis House 17 Godliman Street

London, England, EC4V 5BD,

United Kingdom

+44 (0)20 7090 6190

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Apposite Capital News

Kelso Pharma acquires Stirling Anglian Pharmaceuticals

Jan 12, 2022

Kelso Pharma acquires Stirling Anglian Pharmaceuticals The deal gives the firm a UK platform for further acquisitions and European growth Dr Tom Stratford, chief executive at Kelso Pharma Sign up to FREE email alerts from businessInsider - Business Newsletter sent Mon to Fri, twice each day with a full week's round up every SatInvalid EmailSomething went wrong, please try again later. Subscribe We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info Thank you for subscribingWe have more newsletters Show me See our privacy notice Apposite Capital and Kelso Pharma have acquired Stirling Anglian Pharmaceuticals. Kelso Pharma is headed by Dr Tom Stratford, previously chief executive at Kyowa Kirin International (KKI), the European and US business arm of Kyowa Kirin, which purchased Scottish Borders-based ProStrakan Group in 2011. He is joined by former KKI chief financial officer Allan Watson, and former KKI general counsel Andrew McLean. The acquisition of Glasgow-based Stirling Anglian - for an undisclosed sum - should provide an initial UK platform for future sales growth through further acquisitions, product in-licensing and geographic expansion within Europe. Stirling Anglian’s brand portfolio includes three medicines that are already in the UK healthcare market. Stratford said: “Our aim is to enhance value for the healthcare system by providing branded medicines that improve the lives of patients in a cost-effective and ethical way. “Stirling Anglian’s business is a perfect fit with that vision and with Apposite Capital’s financial support it provides us with a UK platform from which to grow, not just in the UK but elsewhere, as we build a pan-European specialty pharma business.” Sam Gray, managing partner at private equity firm Apposite added: “We are delighted to be partnering with such a talented and proven team of executives given their phenomenal track record in executing acquisitive and organic growth in the specialty pharmaceuticals sector. “Given its growth profile, the acquisition of Stirling Anglian represents an attractive first entry point into the UK market and we share the ambition of the team to create a significant pan-European business with a focus on innovative affordable medicines.” Don't miss the latest headlines with our twice-daily newsletter - sign up here for free . Read More

Apposite Capital Investments

29 Investments

Apposite Capital has made 29 investments. Their latest investment was in NIMGenetics as part of their Private Equity - II on September 9, 2021.

CBI Logo

Apposite Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/20/2021

Private Equity - II

NIMGenetics

No

1

5/24/2021

Private Equity

Emblation

Yes

1

4/1/2021

Private Equity - II

Medical Imaging Partnership

No

1

4/8/2019

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

1/2/2019

Private Equity

Subscribe to see more

Subscribe to see more

10

Date

9/20/2021

5/24/2021

4/1/2021

4/8/2019

1/2/2019

Round

Private Equity - II

Private Equity

Private Equity - II

Private Equity

Private Equity

Company

NIMGenetics

Emblation

Medical Imaging Partnership

Subscribe to see more

Subscribe to see more

Amount

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Apposite Capital Portfolio Exits

7 Portfolio Exits

Apposite Capital has 7 portfolio exits. Their latest portfolio exit was Ambrx on May 22, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/22/2015

Acq - Fin

1

1/12/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/30/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/22/2013

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

5/16/2013

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/22/2015

1/12/2015

7/30/2014

7/22/2013

5/16/2013

Exit

Acq - Fin

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Apposite Capital Acquisitions

8 Acquisitions

Apposite Capital acquired 8 companies. Their latest acquisition was Crest Optics on November 11, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/11/2021

Series A

$99M

$6.33M

Acq - Fin

1

8/2/2021

Subscribe to see more

$99M

Subscribe to see more

10

5/25/2021

Subscribe to see more

$99M

Subscribe to see more

10

4/1/2021

Subscribe to see more

$99M

Subscribe to see more

10

9/19/2018

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/11/2021

8/2/2021

5/25/2021

4/1/2021

9/19/2018

Investment Stage

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$6.33M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Apposite Capital Fund History

4 Fund Histories

Apposite Capital has 4 funds, including Apposite Healthcare.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/15/2020

Apposite Healthcare

$0.77M

1

6/12/2018

Apposite Healthcare Fund II

Subscribe to see more

Subscribe to see more

$99M

10

3/31/2006

Apposite Healthcare Fund

Subscribe to see more

Subscribe to see more

$99M

10

Friday Street Venture Partners

Subscribe to see more

Subscribe to see more

10

Closing Date

12/15/2020

6/12/2018

3/31/2006

Fund

Apposite Healthcare

Apposite Healthcare Fund II

Apposite Healthcare Fund

Friday Street Venture Partners

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$0.77M

$99M

$99M

Sources

1

10

10

10

Apposite Capital Service Providers

1 Service Provider

Apposite Capital has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Apposite Capital Team

1 Team Member

Apposite Capital has 1 team member, including current Managing Partner, Ford David Porter.

Name

Work History

Title

Status

Ford David Porter

Managing Partner

Current

Name

Ford David Porter

Work History

Title

Managing Partner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.